MedTrace Logo

Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occlusion

NCT02169648 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2014-06-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of intravitreal ranibizumab by determining the pathogenesis of macular edema, which cause a direct effect on visual function. In particular, we focus on the correlation between the treatment effectiveness of ranibizumab and the role of the cytokines involved in the cause of macular edema.

Conditions

  • Macular Edema
  • Branch Retinal Vein Occlusion
  • Central Retinal Vein Occlusion

Interventions

DRUG

ranibizumab

intravitreal injection of 0.50 mg (0.05ml) ranibizumab monthly as needed.

Sponsors & Collaborators

  • Tokyo Medical University

    lead OTHER

Principal Investigators

  • Hidetaka Noma, MD · Hachioji Medical Center, Tokyo Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02169648 on ClinicalTrials.gov